BioPortoDx is an in vitro diagnostics company that is dedicated to saving lives and improving the quality of life through actionable biomarkers. Their products are designed to provide early and specific insights into clinical conditions, helping clinicians make informed decisions and improve patient outcomes. With expertise in antibodies and assay development, BioPortoDx has created a pipeline of novel and compelling products that focus on conditions with significant unmet medical needs.

Their flagship product is The NGAL Test, which aids in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome with severe consequences if not identified and treated early. The NGAL Test allows physicians to identify patients at risk of AKI more rapidly than the current standard of care measurements, enabling earlier intervention and tailored patient management strategies. Headquartered in Hellerup, Denmark, BioPortoDx is listed on the NASDAQ Copenhagen stock exchange.

Their leadership team consists of experienced professionals who bring expertise in various areas, including product development, commercialization, marketing, and operations. BioPortoDx is committed to improving patient care and outcomes by providing innovative and reliable diagnostic solutions